Ouro Fino Saúde Animal Participações S.A (OFSA3) - Cash Flow Conversion Efficiency

Latest as of December 2025: 0.125x

Based on the latest financial reports, Ouro Fino Saúde Animal Participações S.A (OFSA3) has a cash flow conversion efficiency ratio of 0.125x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (R$99.91 Million ≈ $19.60 Million USD) by net assets (R$796.86 Million ≈ $156.36 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Ouro Fino Saúde Animal Participações S.A - Cash Flow Conversion Efficiency Trend (2011–2025)

This chart illustrates how Ouro Fino Saúde Animal Participações S.A's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Ouro Fino Saúde Animal Participações S.A total liabilities for a breakdown of total debt and financial obligations.

Ouro Fino Saúde Animal Participações S.A Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Ouro Fino Saúde Animal Participações S.A ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Fiera Capital Corporation
TO:FSZ
0.138x
Jiangsu Holly Corp
SHG:600128
0.038x
Test Rite International Co Ltd
TW:2908
0.132x
Universal Vision Biotechnology Co Ltd
TWO:3218
0.125x
Nordic Paper Holding AB
ST:NPAPER
0.115x
Prudential plc
LSE:PRU
0.073x
AzureWave Technologies Inc
TW:3694
0.076x
Matrix Service Co
NASDAQ:MTRX
0.245x

Annual Cash Flow Conversion Efficiency for Ouro Fino Saúde Animal Participações S.A (2011–2025)

The table below shows the annual cash flow conversion efficiency of Ouro Fino Saúde Animal Participações S.A from 2011 to 2025. For the full company profile with market capitalisation and key ratios, see OFSA3 market cap overview.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 R$796.86 Million
≈ $156.36 Million
R$99.91 Million
≈ $19.60 Million
0.125x +28.27%
2024-12-31 R$756.40 Million
≈ $148.42 Million
R$73.94 Million
≈ $14.51 Million
0.098x -64.59%
2023-12-31 R$689.39 Million
≈ $135.27 Million
R$190.30 Million
≈ $37.34 Million
0.276x +126.76%
2022-12-31 R$735.95 Million
≈ $144.41 Million
R$89.59 Million
≈ $17.58 Million
0.122x +67.93%
2021-12-31 R$641.45 Million
≈ $125.86 Million
R$46.50 Million
≈ $9.12 Million
0.072x -63.68%
2020-12-31 R$560.78 Million
≈ $110.03 Million
R$111.94 Million
≈ $21.96 Million
0.200x +74.32%
2019-12-31 R$492.45 Million
≈ $96.63 Million
R$56.39 Million
≈ $11.06 Million
0.115x +21.96%
2018-12-31 R$455.94 Million
≈ $89.46 Million
R$42.81 Million
≈ $8.40 Million
0.094x -61.70%
2017-12-31 R$405.88 Million
≈ $79.64 Million
R$99.50 Million
≈ $19.52 Million
0.245x +118.41%
2016-12-31 R$376.33 Million
≈ $73.84 Million
R$42.24 Million
≈ $8.29 Million
0.112x +175.25%
2015-12-31 R$380.31 Million
≈ $74.62 Million
R$15.51 Million
≈ $3.04 Million
0.041x +1478.41%
2014-12-31 R$330.16 Million
≈ $64.78 Million
R$853.00K
≈ $167.37K
0.003x -98.38%
2013-12-31 R$209.42 Million
≈ $41.09 Million
R$33.45 Million
≈ $6.56 Million
0.160x -6.07%
2012-12-31 R$194.84 Million
≈ $38.23 Million
R$33.13 Million
≈ $6.50 Million
0.170x +114.04%
2011-12-31 R$177.44 Million
≈ $34.82 Million
R$14.10 Million
≈ $2.77 Million
0.079x --

About Ouro Fino Saúde Animal Participações S.A

SA:OFSA3 Brazil Drug Manufacturers - Specialty & Generic
Market Cap
$342.78 Million
R$1.75 Billion BRL
Market Cap Rank
#14447 Global
#139 in Brazil
Share Price
R$32.49
Change (1 day)
-1.07%
52-Week Range
R$20.90 - R$33.78
All Time High
R$40.76
About

Ouro Fino Saúde Animal Participações S.A., together with its subsidiaries, engages in the development, production, and sale of veterinary drugs, vaccines, and other products for production and companion animals primarily in Brazil. The company operates through three segments: Production Animals; Companion Animals; and International Operations. It manufactures and trades in medicines, including an… Read more